New York, NY, May 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences and Pharmaceutical...
Company Sets New Quarterly Record for Number of Individual E-Commerce Order Transactions New York, NY, March 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Tauriga Sciences, Inc. (OTCQB:...
New York, NY, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Retail Life Sciences and...
New York, NY, Dec. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- TauriganSciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York nbased diversified Life Sciences Company, today announced that it has nformally submitted its Clinical Study Protocol (“Protocol”) to the nInstitutional Review Board (“IRB”). The Company’s Protocol Title: “The Effect of CBD Gum on Nausea and Vomiting During Pregnancy”.
NEW YORK, NY, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, has today reported continued strength and accelerating growth in its highest margin E-Commerce business segment (“E-Comm”). The Company generated strong monthly E-Comm sales for the recently completed month of October 2021. As of today’s date, November 5, 2021, the Company is firmly on track to generate record quarterly E-Comm sales – for its current operating quarter (October 1st– December 31st 2021).
NEW YORK, NY, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has received Notice of Publication from U.S. Patent and Trademark Office (“USPTO”), for its U.S. Patent Application No. 17/204,106. The Company filed this U.S. Patent Application on March 17, 2021 and it related to its ongoing Pharmaceutical development efforts.
NEW YORK, NY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has received notification from the Patent Cooperation Treaty (“PCT”) that its International Patent Application (App No. PCT/US21/22668) was Published (Publication No. WO2021/188612) on September 23, 2021.
Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that its proprietary product offerings are now available on Amazon Prime. Currently, 3 SKUs of the Company’s flagship brand Tauri-Gum™, as well as its Tauri-Pet™ dog treats – are available to Amazon Prime customers.